As more and more delivery firms set their sights on the specialty pharma sector, existing specialty players are increasingly abandoning established licensing strategies in favour of developing drugs in-house to compete.
Like countless pets after every Christmas, it seems that nobody
wanted Biogen Idec after all; the firm has announced it will remain
independent after it 'did not receive any definitive offers to
purchase the company'.
Biogen Idec has announced it is seeking a buyer for the company and
has already received several expressions of interest - including a
reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl
A team of scientists at Biogen Idec have unveiled preclinical data
for a potential protein therapeutic to treat Alzheimer's, a disease
normally only attacked using small molecules due to delivery
Serono has announced a mixed third quarter 2005 with product sales
and total revenues weaker than predicted. Its net income beat
market consensus but the company was hit by an $18.3 million (€15.2
million) one-off charge related to...
US biotechnology company Biogen Idec has succumbed to the effects
of having to withdraw its multiple sclerosis drug Tysabri
(natalizumab) earlier this year, cutting 17 per cent of its
workforce and putting manufacturing facilities...
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
US biotechnology company Biogen Idec has said that it plans to sell
a California manufacturing plant built to produce its withdrawn
multiple sclerosis drug Tysabri (natalizumab) to Genentech,
reports Phil Taylor.
Ireland's largest home grown pharmaceutical company, Elan Holdings,
could be split up into two separate units, one focussing on
biotechnology and the other on manufacturing and drug delivery,
according to UK news reports.
The first in a completely new class of drug for multiple sclerosis
has been approved in the US, opening up a new avenue of treatment
for sufferers of the debilitating diseases and potential
blockbuster revenues for developers Elan...